Responding to Payor Policy Changes That Impact Patients with Postparalytic Facial Palsy: Chemodenervation with Botulinum Toxin

Abstract

Get full access to this article

View all access options for this article.

References

Jowett

. A general approach to facial palsy. Otolaryngol Clin North Am. 2018; 51(6):1019–1031.

Miller

, Hadlock

. Beyond botox: contemporary management of nonflaccid facial palsy. Facial Plast Surg Aesthet Med. 2020; 22(2):65–70.

Mehta

, Hadlock

. Botulinum toxin and quality of life in patients with facial paralysis. Arch Facial Plast Surg. 2008; 10(2):84–87.

Azizzadeh

, Irvine

, Diels

, et al. Modified selective neurectomy for the treatment of post-facial paralysis synkinesis. Plast Reconstr Surg. 2019; 143(5):1483–1496.

Shtraks

, Mirocha

, Azizzadeh

. Quality of life outcomes after modified selective neurectomy for postfacial paralysis synkinesis. Facial Plast Surg Aesthet Med. 2021; 23(6):443–448.

Ferrari

, Manca

, Tugnoli

, Alberto

. Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal. Funct Neurol. 2018; 33(1):7–18.

Shinn

, Nwabueze

, Du

, et al. Treatment patterns and outcomes in botulinum therapy for patients with facial synkinesis. JAMA Facial Plast Surg. 2019; 21(3):244–251.

Thomas

, Larson

, Braden

, Cannon

, Ward

. Effect of 3 commercially available botulinum toxin neuromodulators on facial synkinesis: a randomized clinical trial. JAMA Facial Plast Surg. 2018; 20(2):141–147.